Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin

Journal of the American College of Cardiology

Volumn 35, Issue 7, 2000, Pages 1801-1807

  Latini, Roberto ^a   Tognoni, Gianni ^a   Maggioni, Aldo P ^a,b   Baigent, Colin ^c   Braunwald, Eugene ^d   Chen, Zheng Ming ^c   Collins, Rory ^c   Flather, Marcus ^e   Franzosi, Mariagrazia ^a   Kjekshus, John ^f   Køber, Lars ^g   Liu, Li Sheng ^h   Peto, Richard ^c   Pfeffer, Marc ^d   Pizzetti, Fabrizio ⁱ   Santoro, Eugenio ^a   Sleight, Peter ^c   Swedberg, Karl ^j   Tavazzi, Luigi ^k   Wang, Wen ^h   Yusuf, Salim ^l   more..

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b ANMCO RESEARCH CENTER   (Italy)

^c RADCLIFFE INFIRMARY   (United Kingdom)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

^f UNIVERSITY OF OSLO   (Norway)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

^h FUWAI HOSPITAL   (China)

ⁱ Ospedale S Spirito Casale Monferrato   (Italy)

^j UNIVERSITY OF GOTHENBURG   (Sweden)

^k FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^l HAMILTON GENERAL HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FIBRINOLYTIC AGENT; LISINOPRIL; PROSTAGLANDIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG USE; FEMALE; HUMAN; HYPOTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; CYCLOOXYGENASE INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; TIME FACTORS;

EID: 18344407031     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(00)00638-0     Document Type: Article

References (26)

1. Pfeffer M.A., Braunwald E., Moyé L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction results of the Survival and Ventricular Enlargement Trial (SAVE) . N Engl J Med. 327:1992;669-677.
2. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 342:1993;821-828.
3. Kober L., Torp-Pedersen C., Carlsen J.E., et al. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 333:1995;1670-1676.
4. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction interim report from the Chinese Cardiac Study (CCS-1) . Lancet. 345:1995;686-687.
5. Swedberg K., Held P., Kjekshus J., Rasmussen K., Rydén L., Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. N Engl J Med. 327:1992;678-684.
6. GISSI-3 effects of lisinopril and transdermal glyceryl trinitrate singly and together on six-week mortality and ventricular function after acute myocardial infarction . Lancet. 343:1994;1115-1122.
7. ISIS-4 a randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction . Lancet. 345:1995;669-685.
8. Ambrosioni E., Borghi C., Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med. 332:1995;80-85.
9. Indications for ACE inhibitors in early treatment of acute myocardial infarction. Systematic overview of individual data from 100,000 patients in randomized trials. Circulation. 97:1998;2202-2212.
10. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction ISIS-2 . Lancet. ii:1988;349-360.
11. Collaborative overview of randomized trials of antiplatelet therapy. I Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients . Br Med J. 308:1994;81-106.
12. Blais C., Drapeau G., Raymond P., et al. Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin an interspecies study . Am J Physiol. 273:1997;H2263-H2271.
13. Swartz S.L., Williams G.H., Hollenberg N.K., Levine L., Dluhy R.G., Moore T.J. Captopril-induced changes in prostaglandin production. Relationship to vascular responses in normal man. J Clin Invest. 65:1980;1257-1264.
14. Packer M. Interaction of prostaglandins and angiotensin II in the modulation of renal function in congestive heart failure. Circulation. 77:(Suppl I):1988;I64-I73.
15. Zucker I.H., Chen J.-S., Wang W. Renal sympathetic nerve and hemodynamic responses to captopril in conscious dogs role of prostaglandins . Am J Physiol. 260:1991;H260-H266.
16. Heesch C.M., Crandall E., Turbek J.A. Converting enzyme inhibitors cause pressure-independent resetting of baroreflex control of sympathetic outflow. Am J Physiol. 270:1996;R728-R737.
17. Sturrock N.D.C., Struthers A.D. Nonsteroidal anti-inflammatory drugs and angiotensin converting enzyme inhibitors a commonly prescribed combination with variable effects on renal function . Br J Clin Pharmac. 35:1993;343-348.
18. Brooks P.M., Day R.O. Nonsteroidal antiinflammatory drugs - differences and similarities. N Engl J Med. 324:1991;1716-1725.
19. Hall D., Zeitler H., Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol. 20:1992;1549-1555.
20. Spaulding C., Charbonnier B., Cohen-Solal A., et al. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril. Circulation. 98:1998;757-765.
21. Baur L.H.B., Schipperheyn J.J., van der Laarse A., et al. Combining salicylate and enalapril in patients with coronary artery disease and heart failure. Br Heart J. 73:1995;227-236.
22. Pitt B., Yusuf S. Studies of left ventricular dysfunction (SOLVD) subgroup results . J Am Coll Cardiol. 19:1992;215A.
23. Nguyen K.N., Aursnes I., Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) . Am J Cardiol. 79:1997;115-119.
24. Oosterga M., Anthonio R.L., de Kam P.-J., Kingma J.H., Crijns H.J.G.M., van Gilst W.H. Effects of aspirin on angiotensin-converting enzyme inhibition and left ventricular dilation one year after acute myocardial infarction. Am J Cardiol. 81:1998;1178-1181.
25. Leor J., Riecher-Reiss H., Goldbrourt U., et al. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors. A cohort study of 11,575 patients with coronary artery disease. J Am Coll Cardiol. 33:1999;1920-1925.
26. Krumholz H.M., Radford M.J., Ellerbeck E.F., et al. Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries patterns of use and outcomes . Circulation. 92:1995;2841-2847.